{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:00:42Z","timestamp":1785193242875,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jfma.2025.05.011","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T23:31:24Z","timestamp":1747092684000},"page":"947-953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive factors and clinical outcomes in decompensated non-cirrhotic chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-4858","authenticated-orcid":false,"given":"Yi-Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Sing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Chia","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Wu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-3039","authenticated-orcid":false,"given":"Yen-Chun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Chung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.05.011_bib1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2025.05.011_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/liv.12060","article-title":"Optimal management of HBV infection during pregnancy","volume":"33","author":"Piratvisuth","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2025.05.011_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2025.05.011_bib5","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib6","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/jgh.13213","article-title":"Acute on chronic liver failure because of acute hepatic insults: etiologies, course, extrahepatic organ failure and predictors of mortality","volume":"31","author":"Shalimar","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.05.011_bib8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1136\/gutjnl-2017-314641","article-title":"Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure","volume":"67","author":"Wu","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2025.05.011_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.05.011_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12072-022-10357-0","article-title":"Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.05.011_bib14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jhep.2005.01.019","article-title":"Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score","volume":"42","author":"Huo","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jhep.2014.02.013","article-title":"Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation","volume":"60","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cgh.2010.02.023","article-title":"Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B","volume":"8","author":"Jeng","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib17","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00261-15","article-title":"Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation","volume":"59","author":"Hung","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2025.05.011_bib18","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"Fung","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2025.05.011_bib19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s12072-022-10411-x","article-title":"Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort","volume":"16","author":"Hsu","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.05.011_bib20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5009\/gnl220122","article-title":"Long-term hepatitis B surface antigen profile and seroclearance after severe acute flares of chronic hepatitis B","volume":"17","author":"Hui","year":"2023","journal-title":"Gut Liver"},{"key":"10.1016\/j.jfma.2025.05.011_bib21","first-page":"E89","article-title":"Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: a long-term follow-up study","volume":"46","author":"Nagaoka","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.05.011_bib22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.05.011_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jir283","article-title":"Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"204","author":"Chan","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.05.011_bib24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2025.05.011_bib25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic Review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2025.05.011_bib26","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s10620-019-05614-6","article-title":"Early hepatitis B surface antigen seroclearance following antiviral treatment in patients with reactivation of resolved hepatitis B","volume":"64","author":"Lee","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jfma.2025.05.011_bib27","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.05.011_bib28","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2025.05.011_bib29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.13564","article-title":"Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy","volume":"38","author":"Hsu","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2025.05.011_bib30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:45:36Z","timestamp":1785192336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625002220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0929664625002220"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.05.011","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors and clinical outcomes in decompensated non-cirrhotic chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved.","name":"copyright","label":"Copyright"}]}}